The buy and bill model has long been central to U.S. healthcare reimbursement, especially for provider-administered drugs and specialty therapies in oncology, rheumatology, gastroenterology, and hospital outpatient settings.
Understanding how this model works is essential for every stakeholder involved. For many, the model seems straightforward.
Providers purchase medications, administer specialty drugs to patients, and then bill payers for reimbursement under the patient’s medical benefit.
But beneath that simplicity lies a complex distribution model shaped by regulation, margin pressures, payer policies, and access challenges that vary widely across states and disease areas.
We will explore the buy-and-bill process in depth, examining benefits and drawbacks, how different stakeholders experience it, and why conversations about alternatives, especially white bagging and pharmacy benefit models are becoming louder each year.
How the Buy-and-Bill Model Works
At its core, buy-and-bill begins when a healthcare provider purchases drugs directly, either through distributors or group purchasing organizations. They hold these medications onsite until the treatment appointment arrives.
The provider stores and manages inventory, ensures chain-of-custody compliance, and administers specialty drugs, often complex biologics that require precision dosing and clinically supervised infusion.
Once therapy is provided, the clinic or hospital submits a claim for reimbursement under the patient’s medical benefit. The payer, whether Medicare, a commercial third-party payer, or Medicaid, evaluates the claim and issues payment based on average sales price or contract-negotiated reimbursement rates.
The process appears linear, yet it’s heavily influenced by coding accuracy, medical necessity documentation, and timing.
This is why the reimbursement process requires specialized staff who understand billing not only for the drug itself, but also for administering the medication, managing follow-ups, and handling audits.
When executed efficiently, the buy-and-bill model offers several operational and clinical advantages that make it attractive to providers who need control over their treatment protocols.
Why Providers Still Choose Buy-and-Bill
Despite the complexity and financial exposure, medical practices that administer biologic or infusion therapies continue using buy-and-bill for one primary reason: autonomy and immediate access.
Under this model, physicians schedule care based on clinical need rather than shipping schedules or external carrier delays. Patients can begin therapy more quickly, and providers can modify specialty drug dosage on the spot if weight changes, toxicity requires adjustment, or adverse events occur.
This flexibility is critical in oncology and immunology settings where patient conditions can shift rapidly between appointments.
For clinics, the model also offers revenue opportunity because they receive reimbursement for both the procedure and the product. Providers may purchase drugs at preferred pricing through group purchasing organizations, and in some cases receive higher reimbursement when negotiated rates align favorably, leading to better margins compared to other models.
Beyond revenue considerations, buy-and-bill allows physicians and not intermediaries to determine appropriate therapy and timing. That clinical control aligns with emerging value-based care goals: appropriate treatment, at the right moment, for the right patient.
The model also eliminates the uncertainty of drug availability at the point of care. When providers manage their own inventory, they know exactly what’s available and can plan treatment schedules accordingly.
The Real Challenges of Buy-and-Bill Model
However, the picture isn’t unanimously positive. The healthcare system has become increasingly complex, and the financial realities of the buy and bill specialty model are significant.
Providers take on substantial financial risk by holding costly specialty pharmaceuticals, sometimes valued between $10,000 and $40,000 per dose.
If a patient cancels an appointment, insurance denies coverage, or clinical deterioration prevents treatment, the provider often absorbs the loss because the drug cannot safely reenter the supply chain.
There’s also the considerable burden of inventory management. Temperature monitoring systems, spoilage risk mitigation, and credentialing requirements all add operational cost. For smaller practices, these infrastructure demands can be prohibitive.
Compliance matters deeply too, and payers increasingly demand documented prior authorization before approving reimbursement, making a prior authorization certified specialist nearly a necessity for infusion centers that want to avoid claim denials.
For oncology and immunology practices in particular, the volatility of reimbursement impacts long-term sustainability. The challenges of using average sales price to reimburse outpatient oncology practices include delayed pricing updates, sudden shifts in margin, and policy revisions that don’t reflect real-market pricing changes or acquisition costs.
Practices operating on thin margins feel these pressures acutely, and some have been forced to stop offering certain therapies or limit the number of patients they can treat.
This means the buy-and-bill approach isn’t simply a clinical workflow, it’s a financial strategy and operational capability that must be planned and resourced carefully.
Role of Stakeholders Across the Buy-and-Bill Ecosystem
Understanding the model fully requires seeing how each stakeholder experiences it differently and what motivates their preferences.
Pharma Manufacturers
For pharmaceutical companies, market access success often relies heavily on provider comfort with the buy-and-bill process. Pharma teams must educate providers on product stability requirements, reimbursement pathways, and coverage considerations under patient’s medical benefit versus pharmacy benefit pathways.
The upside for manufacturers is greater control over distribution and speed to market. The downside is increased scrutiny around pricing and cost trends that can lead to policy interventions.
Pharma companies also bear responsibility for providing hub services, reimbursement support, and patient assistance programs that help make the buy-and-bill model work smoothly for providers and patients.
Patients
From the patient perspective, the model simplifies treatment logistics because everything occurs in one clinical location. There’s no need to coordinate with external pharmacies or manage drug transport.
However, out-of-pocket costs vary significantly depending on benefit design under the patient’s insurance. Deductibles, copays, and coinsurance for specialty drug therapy can create substantial financial burden, particularly early in the calendar year before deductibles are met.
Patients also benefit from the clinical oversight that comes with in-office administration. Providers can immediately address infusion reactions or side effects, providing a safety net that’s harder to achieve with home-administered therapies.
Providers
Providers benefit from operational efficiency and continuity of care, but they assume considerable financial and administrative risk. The healthcare provider purchases the drug upfront, must prove medical necessity through documentation, and then waits for payment that may take weeks or months.
For many physician practices, reimbursement uncertainty is as important a consideration as clinical outcomes when deciding which therapies to offer.
Providers also face the ongoing challenge of staying current with changing payer policies, prior authorization requirements, and billing code updates that affect their ability to receive timely payment.
Payers
For payers, cost control remains the top priority. The appeal of alternatives, particularly white bagging, where specialty pharmacies control distribution, is primarily about cost transparency and the ability to negotiate directly with pharmacy benefit managers.
Yet payers and providers disagree fundamentally on whether these alternatives improve patient care or simply shift responsibility and risk away from payers onto providers and patients.
Payers also argue that better oversight through specialty pharmacy channels can improve adherence and outcomes, though evidence supporting this claim in the infused therapy setting remains mixed.
The Rise of Specialty Pharmacy in Buy-and-Bill
A specialty pharmacy plays an increasingly important role as the industry considers shifts away from traditional buy-and-bill models.
These pharmacies handle patient education, side-effect support, refill management, and cold-chain logistics for complex biologics, biosimilars, and gene therapies that require special handling.
As costs for these therapies continue rising, some payers believe that relying on specialty pharmacy channels gives them tighter control over utilization and spending. Specialty pharmacies can implement step therapy protocols, conduct clinical outreach, and monitor adherence more systematically.
However, critics argue that shipping externally delivered drugs introduces delays and can jeopardize patient safety if doses must be modified at the chairside based on real-time clinical assessment.
This ongoing debate has opened the door to alternative distribution models that attempt to balance cost control with clinical flexibility.
Alternatives to Buy-and-Bill
There are three main alternatives to the traditional buy-and-bill model, each with distinct implications:
White bagging: The drug is shipped directly to the provider’s office from a specialty pharmacy designated by the payer. The provider administers it but doesn’t purchase or own the medication.
Clear bagging: A hospital-owned or hospital-affiliated pharmacy dispenses medications to its own clinics, keeping the process within one health system.
Brown bagging: The patient personally transports the drug from an external pharmacy to the provider’s office. This approach is rare and generally not favored due to safety and liability concerns.
These models fundamentally shift who manages cost, logistics, and inventory risk. They also reshape clinical responsibility: in some cases, the specialty pharmacy or third-party payer must oversee the drug before administration, which limits provider control over treatment timing and dosing decisions.
White bagging in particular has become controversial. Providers argue it introduces delays, creates waste when patients no-show, and prevents real-time dose adjustments. Payers counter that it reduces inappropriate utilization and provides better cost visibility.
Medicare Buy and Bill and the Policy Landscape
For Medicare patients, the buy and bill model continues primarily through Medicare Part B, which covers most infusion therapy and oncology drugs under medical benefit coverage rather than Part D pharmacy benefits.
However, reimbursement aligned to average sales price plus a fixed percentage doesn’t always reflect real acquisition costs that providers pay, especially when there are shortages, distribution issues, or rapid price changes.
Policy change remains ongoing, and value-based programs emerging through the Centers for Medicare & Medicaid Services suggest that how providers purchase drugs and how they bill payers may evolve significantly in coming years.
For now, Medicare remains a significant driver of the buy-and-bill model and shapes how commercial payers structure their own policies in response.
The interplay between Medicare policy and commercial insurance creates complexity for providers who must navigate different rules for different patient populations.
Stakeholder Perspectives at a Glance
- For Pharma: The buy-and-bill model shapes launch strategy, market access plans, and distribution model decisions. It affects how quickly new therapies reach patients.
- For Providers: It creates clinical autonomy and operational control but increases exposure to delayed reimbursement and financial risk from inventory holding.
- For Patients: It typically improves convenience and care continuity, though out-of-pocket costs can be burdensome depending on insurance design.
- For Payers: It demands careful balance between cost oversight, utilization management, and clinical urgency while maintaining network adequacy.
Whether buy-and-bill continues in its current form depends on the industry’s collective ability to balance innovation, affordability, and patient outcomes.
Getting Started with Buy-and-Bill
Organizations preparing to begin or expand buy-and-bill operations should focus on several critical areas.
First, develop robust inventory management capability that can handle high-value specialty drugs safely while minimizing waste and spoilage.
Second, invest in training staff on billing accuracy and reimbursement processes specific to specialty drugs, which differ significantly from standard pharmaceutical billing.
Third, establish strong logistics relationships and supply chain safeguards to ensure continuity even during shortages or distribution disruptions.
Fourth, implement documentation systems that support audits, outcomes tracking, and prior authorization requirements that payers increasingly mandate.
Fifth, build organizational flexibility to accommodate value-based payment initiatives and alternative payment models that may emerge.
Successful setups begin not by asking whether you can purchase the drug, but whether you can handle reimbursement uncertainty and operational complexity while maintaining high standards of patient care.
Looking Forward
The buy-and-bill model remains the most trusted pathway for provider-administered drugs today. It allows immediate access to treatment and gives clinicians the discretion to adjust therapies in real time based on patient response.
Yet the model also places considerable burden on providers, both financially and administratively, that smaller practices may struggle to sustain.
The future will likely include a blend of buy-and-bill, white bagging, and evolving pharmacy-integrated models shaped by payer strategy, manufacturing innovation, and policy reform from both state and federal regulators.
No single model is perfect for every situation, every patient, or every clinical setting. Each approach involves tradeoffs between cost, convenience, clinical control, and patient safety.
But the mission remains clear: to deliver safe, effective, timely care through systems that balance access with long-term sustainability.
Whether you’re a pharmaceutical company developing launch strategies, a healthcare provider managing clinical operations, a payer designing benefit structures, or a patient navigating treatment options, understanding the nuances of buy-and-bill and its alternatives is essential to navigating the modern specialty pharmacy and reimbursement landscape successfully.